Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings Inc (BPTH) is a clinical-stage biotechnology company pioneering targeted therapies using its proprietary DNAbilize® platform, which enhances delivery of nucleic acid-based cancer treatments. This page provides investors and industry professionals with timely updates on BPTH pipeline progress, regulatory milestones, and corporate developments.
Access consolidated news about clinical trial results, partnership announcements, and financial reports in one trusted location. Content spans preclinical advancements, FDA communications, and strategic initiatives shaping the company’s oncology focus.
Key updates include developments in antisense DNA therapeutics for blood cancers and solid tumors, leveraging BPTH’s novel liposomal delivery system. Bookmark this page to efficiently track the company’s progress in advancing precision medicine solutions with improved safety profiles.
Bio-Path Holdings (NASDAQ:BPTH) reported its financial results for 2022, showing a net loss of $13.9 million or $1.91 per share, compared to a loss of $10.4 million the previous year. Research and development expenses rose to $9.2 million, attributed to increased clinical trial activities. As of December 31, 2022, the company had $10.4 million in cash, a decrease from $23.8 million in 2021. Key clinical milestones include the first patient dosed in the BP1001-A Phase 1/1b trial for solid tumors and ongoing trials for AML. The company remains optimistic about progressing through its 2023 milestones.
FAQ
What is the current stock price of Bio-Path Hldgs (BPTH)?
What is the market cap of Bio-Path Hldgs (BPTH)?
